SCHEMBL6653574

SCHEMBL6653574

NC(CS(=O)(=O)Cc1ccccc1)C(=O)N[C@H](CCc1ccccc1)[C@H](O)c1nccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.40
CTSC P53634 4/20 0.40
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSPA1A P0DMV8 1/20 0.37
HSPA5 P11021 1/20 0.37
HSPA9 P38646 1/20 0.37
HSPA2 P54652 1/20 0.37
PTPRB P23467 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CTSB P07858 1/20 0.36
CTSH P09668 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
F10 P00742 2/20 0.34
LMNA P02545 1/20 0.34
PLA2G4A P47712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6653578 1.00 ADAM17 (0.40) ADAM17CTSCALDH1A1HPGDHSPA1A
SCHEMBL6653571 1.00 ADAM17 (0.40) ADAM17CTSCALDH1A1HPGDHSPA1A
SCHEMBL6686548 1.00 ADAM17 (0.40) ADAM17CTSCALDH1A1HPGDHSPA1A
SCHEMBL6628049 0.82 CTSK (0.44) PTPRBCTSBCTSSCTSKCTSL
SCHEMBL6628052 0.82 CTSK (0.44) PTPRBCTSBCTSSCTSKCTSL
SCHEMBL6628047 0.82 CTSK (0.44) PTPRBCTSBCTSSCTSKCTSL
SCHEMBL6702656 0.82 CTSK (0.44) PTPRBCTSBCTSSCTSKCTSL
SCHEMBL6680450 0.80 ADAM17 (0.43) ADAM17PTPRBHDAC6SMN1; SMN2L3MBTL1
SCHEMBL6468744 0.76 ALDH1A1 (0.39) CTSCALDH1A1CTSBCTSHCTSS
Hydrochloric Acid SCHEMBL6465933 0.75 ALDH1A1 (0.38) CTSCALDH1A1CTSBCTSHCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE ADAM17 65/4885CTSC 13/4885ALDH1A1 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.